17Apr

Novodiag® Bacterial GE+, a new diagnostic test for on-demand detection of bacterial pathogens

Espoo, Finland, April 17th, 2018 - Mobidiag, a Finnish molecular diagnostics company, today announced the launch of Novodiag® Bacterial GE+, a molecular diagnostic test for the simultaneous detection of most common enteric pathogens directly from stool samples. Compatible with the fully automated Novodiag® system launched at the end of 2017, this new disposable cartridge allows direct analysis of a patient sample and delivers comprehensive results in about an hour, compared to days with currently used culture methods.

“The new Novodiag Bacterial GE+ cartridge can identify dozens of targets, including the majority of bacteria causing diarrhea. Thanks to its simplified and optimized workflow, our fully automated Novodiag solution can support early decision making prior to any treatment delivery and improve patient care by managing infections accordingly” explains Tuomas Tenkanen. “We are very proud to now offer the first syndromic test compatible with our Novodiag system. Our ambition is to make accessible one of the most relevant range of test panels. We are currently working on extending our product line and address among others the detection of antibiotic resistances to improve the correct use of antibiotics”.

Novodiag® Bacterial GE+ test is now available directly through Mobidiag and local distributors. For more information, visit our product page.

About Novodiag® (CE-IVD) The Novodiag solution allows direct analysis of a patient sample placed in a disposable cartridge and delivers comprehensive results in about an hour. Combining qPCR and microarray technologies, Novodiag offers an all in one solution for on-demand targeted and syndromic testing.

This molecular diagnostic solution offers an easy to use and cost-efficient method, with very limited hands-on-time and without the need for much technical expertise. Novodiag is suitable for all test volumes and on demand testing for clinical laboratories. Learn more about Novodiag.

About Mobidiag Ltd. Established in 2000, Mobidiag develops and commercializes innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with an R&D center in France and subsidiaries in UK and Sweden.

Combining Amplidiag and Novodiag solutions, Mobidiag offers a comprehensive line of products for fast, reliable and cost-efficient diagnostics for infectious diseases and antibiotic resistances. Mobidiag is able to cover all laboratories requirements no matter their size, throughput and centralized/ decentralized organization.

To learn more, visit mobidiag.com or contact: Dorothee Allard +33 1 55 25 17 13
marketing@mobidiag.com

Related

Member Press Release - Life Science Group receives ISO 13485 accreditation

Life Science Group receives ISO 13485 accreditation. Life Science Group (LSG), one of the UK...

Read More >

Biofortuna expands its immunoassay development and manufacturing services

Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, ...

Read More >

BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project

BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic dev...

Read More >

EKF introduces accurate quantitative COVID-19 antibody test kit

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and ...

Read More >

Collaboration secures approximately £20,000 to enhance expert support to diagnostic test developers

A collaboration between the North East Innovation Lab and the National Institute for Health and Care...

Read More >

BBI Solutions broadens antibody portfolio and strengthens reagent technical support capabilities with acquisition of Maine Biotechnology Services

BBI Solutions (BBI) has announced the addition of over 80 new antibodies to its growing product port...

Read More >